Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists

Jia Jin Chen; Tao Han Lee; Huang Yu Yang

doi:10.1016/j.kint.2024.01.002

Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists

Jia Jin Chen
, Tao Han Lee
, Huang Yu Yang^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Abstract

This commentary provides an analysis of the study by Fu et al. in Kidney International, which employs 3 administrative databases to investigate the hyperkalemia protective effects of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors. It emphasizes the methodological approach, notably the use of a fixed-effect model to aggregate pairwise comparisons from 3 data sets. In addition, we explored the broader cardiorenal and potential nonrenal benefits of these drug classes, underscoring the imperative for continued research in this domain.

Original language	English
Pages (from-to)	442-444
Number of pages	3
Journal	Kidney International
Volume	105
Issue number	3
DOIs	https://doi.org/10.1016/j.kint.2024.01.002
State	Published - 03 2024
Externally published	Yes

Bibliographical note

Keywords

Humans
Sodium-Glucose Transporter 2 Inhibitors/adverse effects
Hypoglycemic Agents/adverse effects
Diabetes Mellitus, Type 2/complications
Glucagon-Like Peptide-1 Receptor Agonists
Dipeptidyl-Peptidase IV Inhibitors/adverse effects
Glucagon-Like Peptide-1 Receptor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.kint.2024.01.002

Cite this

@article{422d1f798173481e8943a39e126a6c5d,

title = "Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists",

abstract = "This commentary provides an analysis of the study by Fu et al. in Kidney International, which employs 3 administrative databases to investigate the hyperkalemia protective effects of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors. It emphasizes the methodological approach, notably the use of a fixed-effect model to aggregate pairwise comparisons from 3 data sets. In addition, we explored the broader cardiorenal and potential nonrenal benefits of these drug classes, underscoring the imperative for continued research in this domain.",

keywords = "Humans, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, Hypoglycemic Agents/adverse effects, Diabetes Mellitus, Type 2/complications, Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl-Peptidase IV Inhibitors/adverse effects, Glucagon-Like Peptide-1 Receptor",

author = "Chen, \{Jia Jin\} and Lee, \{Tao Han\} and Yang, \{Huang Yu\}",

year = "2024",

month = mar,

doi = "10.1016/j.kint.2024.01.002",

language = "英语",

volume = "105",

pages = "442--444",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Elsevier B.V.",

number = "3",

}

TY - JOUR

T1 - Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists

AU - Chen, Jia Jin

AU - Lee, Tao Han

AU - Yang, Huang Yu

PY - 2024/3

Y1 - 2024/3

N2 - This commentary provides an analysis of the study by Fu et al. in Kidney International, which employs 3 administrative databases to investigate the hyperkalemia protective effects of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors. It emphasizes the methodological approach, notably the use of a fixed-effect model to aggregate pairwise comparisons from 3 data sets. In addition, we explored the broader cardiorenal and potential nonrenal benefits of these drug classes, underscoring the imperative for continued research in this domain.

AB - This commentary provides an analysis of the study by Fu et al. in Kidney International, which employs 3 administrative databases to investigate the hyperkalemia protective effects of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors. It emphasizes the methodological approach, notably the use of a fixed-effect model to aggregate pairwise comparisons from 3 data sets. In addition, we explored the broader cardiorenal and potential nonrenal benefits of these drug classes, underscoring the imperative for continued research in this domain.

KW - Humans

KW - Sodium-Glucose Transporter 2 Inhibitors/adverse effects

KW - Hypoglycemic Agents/adverse effects

KW - Diabetes Mellitus, Type 2/complications

KW - Glucagon-Like Peptide-1 Receptor Agonists

KW - Dipeptidyl-Peptidase IV Inhibitors/adverse effects

KW - Glucagon-Like Peptide-1 Receptor

UR - https://www.scopus.com/pages/publications/85184204960

U2 - 10.1016/j.kint.2024.01.002

DO - 10.1016/j.kint.2024.01.002

M3 - 评论/辩论

C2 - 38388145

AN - SCOPUS:85184204960

SN - 0085-2538

VL - 105

SP - 442

EP - 444

JO - Kidney International

JF - Kidney International

IS - 3

ER -

Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this